PPF Group Amends Autolus Therapeutics Stake Filing

TL;DR

PPF Group updated their Autolus Therapeutics stake filing on 10/25/24. Watch for potential moves.

AI Summary

PPF Group N.V. and its affiliates, including AMALAR HOLDING S.R.O. and RENATA KELLNEROVA, filed an amendment to their Schedule 13D on October 25, 2024, regarding their holdings in Autolus Therapeutics plc. This filing indicates a change in their beneficial ownership of the company's American Depositary Shares and ordinary shares.

Why It Matters

This amendment signals a potential shift in significant shareholder activity for Autolus Therapeutics, which could influence the company's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings by major shareholders like PPF Group can indicate strategic shifts or potential future actions that may impact the stock price.

Key Players & Entities

• PPF Group N.V. (company) — Filing entity
• Autolus Therapeutics plc (company) — Subject company
• AMALAR HOLDING S.R.O. (company) — Affiliate of filing entity
• RENATA KELLNEROVA (person) — Affiliate of filing entity
• PPF a.s. (company) — Related entity

FAQ

Key Financial Figures

• $0.000042 — nting one ordinary share, nominal value $0.000042 per share, and ordinary shares, nomina

Filing Documents

• ea0218619-13da10ppf_autolus.htm (SC 13D/A) — 87KB
• ea021861902ex99-1_autolus.htm (EX-99.1) — 9KB
• ea021861902ex99-3_autolus.htm (EX-99.3) — 9KB
• 0001213900-24-090768.txt ( ) — 107KB

Identity and Background

Item 2. Identity and Background. The list of Reporting Persons in Item 2(a) of the Schedule 13D is hereby amended and supplemented to include Amalar, a limited liability company organized and existing under the laws of the Czech Republic. Additionally, the last sentence of the first paragraph of Item 2(a) of the Schedule 13D is hereby amended and restated with the following, which explains the relationship of Amalar to the other Reporting Persons: The principal shareholder of PPF Biotech is PPF Group, and the majority shareholder of PPF Group is Amalar, of which Mrs. Kellnerova is the majority owner. The last sentence of the second paragraph in Item 2(a) of the Schedule 13D is also hereby amended and restated by replacing it with the following: The Reporting Persons have entered into a Joint Filing Agreement dated October 25, 2024, pursuant to Rule 13d-1(k) under the Exchange Act, a copy of which is attached as Exhibit 7.1 to this Amendment No. 10.

(b) of the Schedule

Item 2(b) of the Schedule 13D is hereby amended and supplemented to include the following: The principal business address of Amalar is Evropská 2690/17, P.O. Box 177, 160 41 Prague 6, Czech Republic.

(c) of the Schedule

Item 2(c) of the Schedule 13D is hereby amended and supplemented to include the following: The principal business of Amalar is to act as a holding company for certain investments of Mrs. Kellnerova and her daughters.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby amended and

Item 5 of the Schedule 13D is hereby amended and restated by replacing it with the following: The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The percentage ownership of the ADSs representing Ordinary Shares is calculated based on 266,094,457 Ordinary Shares outstanding (including Ordinary Shares in the form of ADSs) as of August 6, 2024 (as set forth in the Issuer’s quarterly report on Form 10-Q filed with the SEC on August 8, 2024). 6 (a) Aggregate number and percentage of securities PPF Biotech is the owner of record of 14,782,275 Ordinary Shares represented by ADSs beneficially owned, or 5.6% of the Ordinary Shares of the Issuer. Each of the Reporting Persons, as a result of the relationships described in Item 2, may be deemed to directly or indirectly beneficially own the Ordinary Shares held by PPF Biotech. Each of the Reporting Persons disclaims beneficial ownership in all Ordinary Shares reported herein, except to the extent of its respective pecuniary interest therein. See also rows 11 and 13 of the cover pages to this Schedule 13D and Item 2 of this Schedule 13D for the aggregate number of Ordinary Shares beneficially owned by each of the Reporting Persons. The ownership percentages reported in this Schedule 13D are based on 266,094,457 Ordinary Shares outstanding (including Ordinary Shares in the form of ADSs) as of August 6, 2024 (as set forth in the Issuer’s quarterly report on Form 10-Q filed with the SEC on March 17, 2024). (b) Power to vote and dispose See rows 7 through 10 of the cover pages to, and Item 2 of, this Schedule 13D for the number of Ordinary Shares beneficially owned by each of the Reporting Persons as to which there is sole or shared power to vote or to direct the vote, and sole or shared power to dispose or to direct the disposition. (c) Transactions within the past 60 days The reported share amounts for the Reporting Persons reflect amounts as of the date

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits.

of the Schedule 13D is hereby amended to

Item 7 of the Schedule 13D is hereby amended to replace Exhibit 99.1 and to add Exhibit 99.3 as follows: Exhibit 99.1 Joint Filing Agreement, dated as of October 25, 2024. Exhibit 99.3 Power of Attorney of AMALAR HOLDING s.r.o., dated as of August 5, 2024. 7

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 25, 2024 Renata Kellnerova By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact AMALAR HOLDING S.R.O. By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact PPF GROUP N.V. By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact PPF BIOTECH B.V. By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact 8

View Full Filing

View this SC 13D/A filing on SEC EDGAR